Add Company
Join Now

Arbutus Biopharma Corporation Revenue and Competitors

License our Company Data API

Warminster, PA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Arbutus Biopharma Corporation's estimated annual revenue is currently $17.4M per year.(i)
  • Arbutus Biopharma Corporation's estimated revenue per employee is $155,000

Employee Data

  • Arbutus Biopharma Corporation has 112 Employees.(i)
  • Arbutus Biopharma Corporation grew their employee count by -8% last year.

Arbutus Biopharma Corporation's People

NameTitleEmail/Phone
1
VP, BiologyReveal Email/Phone
2
VP Human ResourcesReveal Email/Phone
3
SVP, ControllerReveal Email/Phone
4
VP Investor RelationsReveal Email/Phone
5
VP, FP&A and Collaboration ManagementReveal Email/Phone
6
VP Clinical OperationsReveal Email/Phone
7
Senior Director Clinical OperationsReveal Email/Phone
8
Chief Medical OfficerReveal Email/Phone
9
Senior Director Program Management/Regulatory Affairs LiaisonReveal Email/Phone
10
Senior Director, Regulatory AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Arbutus Biopharma Corporation?

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company’s current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, Arbutus is developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that they intend to combine to improve the outcomes of patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. Arbutus’ lead compound, AB-729 is the only RNAi therapeutic with evidence of immune re-awakening and is currently being evaluated in multiple phase 2 clinical trials. Arbutus has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). Arbutus is also exploring oncology applications for its internal PD-L1 portfolio.

keywords:N/A

N/A

Total Funding

112

Number of Employees

$17.4M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M12812%N/A
#2
$13.2M132-5%N/A
#3
$36.2M134-8%N/A
#4
$56.1M15823%N/A
#5
$15M1998%N/A